Evommune reports Q4/FY2025 net loss $28.3M/$68.9M; positive EVO301 Ph2a data; $125M raise

Evommune, Inc.

Q4 net loss $28.3M; FY net loss $68.9M vs $66.8M prior year. Revenue $13.0M FY (Maruho deal). Cash $216.7M at Dec 31, 2025.
Positive Phase 2a POC data for EVO301 in atopic dermatitis: met primary endpoint, 33% placebo-adjusted EASI reduction at week 12 after 2 doses.
EVO756 Phase 2b top-line data expected 2Q26 for CSU, 2H26 for AD; Phase 2b in migraine to start mid-2026.
Closed $125M private placement in Feb 2026; cash runway extended through 2028.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Evommune, Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue Revenue was $0 million and $13.0 million for the fourth quarter and full year ended December 31, 2025, respectively, net income Net loss totaled $28.3 million and $68.9.

Period: fourth quarter and full year ended December 31, 2025
Revenue: Revenue was $0 million and $13.0 million for the fourth quarter and full year ended December 31, 2025, respectively
Net income: Net loss totaled $28.3 million and $68.9
Result: reported results

Exact text from the filing

Evommune, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the three months and full year ended December 31, 2025

View on SEC.gov

Browse all earnings releases →

Evommune, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-093920

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.